Get the Stockscreener App
31.28
0.06%
-0.02
Amphastar Pharmaceuticals Inc stock is traded at $31.28, with a volume of 498.67K.
It is down -0.06% in the last 24 hours and down -13.18% over the past month.
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
See More
Previous Close:
$31.30
Open:
$31.55
24h Volume:
498.67K
Relative Volume:
0.96
Market Cap:
$1.50B
Revenue:
$723.55M
Net Income/Loss:
$157.72M
P/E Ratio:
10.43
EPS:
3
Net Cash Flow:
$170.15M
1W Performance:
+0.84%
1M Performance:
-13.18%
6M Performance:
-33.26%
1Y Performance:
-38.97%
1-Day Range:
$30.96
$31.60
1-Week Range:
$30.34
$31.65
52-Week Range:
$30.34
$56.38
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Name
Amphastar Pharmaceuticals Inc
Sector
Phone
909-980-9484
Address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
31.28 | 1.50B | 723.55M | 157.72M | 170.15M | 3.00 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-22-24 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Nov-17-23 | Initiated | BofA Securities | Neutral |
| Jul-25-23 | Resumed | Jefferies | Buy |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jul-29-22 | Initiated | CapitalOne | Overweight |
| Jan-07-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-05-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-01-20 | Initiated | Northland Capital | Outperform |
| Mar-13-19 | Downgrade | Needham | Buy → Hold |
| Mar-13-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-10-18 | Reiterated | Needham | Buy |
| Mar-13-18 | Reiterated | Needham | Buy |
| Dec-01-17 | Reiterated | Needham | Buy |
| Nov-09-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-27-17 | Reiterated | Needham | Buy |
| Mar-14-17 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-09-16 | Reiterated | Needham | Buy |
| May-10-16 | Reiterated | Needham | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| Jun-19-15 | Reiterated | Needham | Buy |
| Jun-03-15 | Initiated | Raymond James | Strong Buy |
| Jul-21-14 | Initiated | Needham | Buy |
View All
Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Short Interest Update - MarketBeat
Can Amphastar's High-Value Pipeline Strategy Show Results? Q4 Earnings Preview - StockTitan
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 12-Month LowHere's Why - MarketBeat
Amphastar Pharmaceuticals: A Gradual Strategy (NASDAQ:AMPH) - Seeking Alpha
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference - ACCESS Newswire
Amphastar Pharmaceuticals (AMPH) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Dextrose Injection Market: Demand, Growth, and Innovations 2025-2032 | Pfizer Inc., Amphastar Pharmaceuticals Inc - openPR
Yousif Capital Management LLC Lowers Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
How the (AMPH) price action is used to our Advantage - Stock Traders Daily
State of Alaska Department of Revenue Sells 342 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Polaris Capital Management LLC Buys Shares of 24,500 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks - The Globe and Mail
Amphastar stock hits 52-week low at $31.54 amid market challenges - Investing.com Canada
Amphastar stock hits 52-week low at $34.08 amid market challenges - Investing.com Nigeria
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - Simply Wall St
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap DownShould You Sell? - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Lowered by Piper Sandler - MarketBeat
Boston Trust Walden Corp Purchases 439,281 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 52-Week LowHere's Why - MarketBeat
Piper Sandler Downgrades Amphastar Pharmaceuticals (NASDAQ:AMPH) to Neutral - Defense World
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Sees Large Growth in Short Interest - MarketBeat
Piper Sandler Downgrades Amphastar Pharmaceuticals (AMPH) - MSN
Piper Sandler cuts Amphastar stock rating, slashes price target By Investing.com - Investing.com Canada
Market Resilience: Amphastar Pharmaceuticals Inc (AMPH) Finishes Weak at 33.39, Down -4.24 - The Dwinnex
This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Piper Sandler Downgrades Amphastar Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $36 From $66 - Marketscreener.com
Piper Sandler cuts Amphastar stock rating, slashes price target - MSN
Long Term Trading Analysis for (AMPH) - Stock Traders Daily
Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference - ACCESS Newswire
BofA Adjusts Price Target on Amphastar Pharmaceuticals to $44 From $46 -February 03, 2025 at 10:16 am EST - Marketscreener.com
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Purchased by Pacer Advisors Inc. - MarketBeat
Amphastar Pharmaceuticals is Now Oversold (AMPH) - Nasdaq
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021 - ACCESS Newswire
Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023 - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024 - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024 - ACCESS Newswire
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024 - ACCESS Newswire
Amphastar Receives FDA Approval for Vasopressin - ACCESS Newswire
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference - ACCESS Newswire
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023 - ACCESS Newswire
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program - ACCESS Newswire
(AMPH) Technical Data - Stock Traders Daily
Amphastar Receives FDA Approval for Ganirelix Acetate Injection - ACCESS Newswire
Possible Bearish Signals With Amphastar Pharmaceuticals Insiders Disposing Stock - Simply Wall St
Amphastar Pharmaceuticals Inc Stock (AMPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amphastar Pharmaceuticals Inc Stock (AMPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 12 '24 |
Option Exercise |
11.33 |
7,000 |
79,310 |
125,469 |
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 13 '24 |
Sale |
45.23 |
8,000 |
361,840 |
118,469 |
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 12 '24 |
Sale |
44.42 |
7,000 |
310,975 |
118,469 |
| PRINS RICHARD K | Director |
Dec 09 '24 |
Option Exercise |
19.52 |
10,000 |
195,200 |
40,471 |
| PRINS RICHARD K | Director |
Dec 09 '24 |
Sale |
43.77 |
10,000 |
437,702 |
30,471 |
3.23%
3.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):